Comment
doi: 10.1001/jama.2023.21106.
Use of Donanemab in Early Symptomatic Alzheimer Disease
Affiliations
- PMID: 38112820
- DOI: 10.1001/jama.2023.21106
Item in Clipboard
Comment
Use of Donanemab in Early Symptomatic Alzheimer Disease
JAMA.
.
No abstract available
Comment on
-
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.JAMA. 2023 Aug 8;330(6):512-527. doi: 10.1001/jama.2023.13239. JAMA. 2023. PMID: 37459141 Free PMC article.
Similar articles
-
Use of Donanemab in Early Symptomatic Alzheimer Disease-Reply.JAMA. 2023 Dec 19;330(23):2304-2305. doi: 10.1001/jama.2023.21109. JAMA. 2023. PMID: 38112817 No abstract available.
-
Donanemab: First Approval.Drugs. 2024 Oct;84(10):1313-1318. doi: 10.1007/s40265-024-02087-4. Epub 2024 Sep 6. Drugs. 2024. PMID: 39237715 Review.
-
Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial.JAMA Neurol. 2022 Dec 1;79(12):1250-1259. doi: 10.1001/jamaneurol.2022.3392. JAMA Neurol. 2022. PMID: 36251300 Free PMC article. Clinical Trial.
-
Alzheimer's drug donanemab helps most when taken at earliest disease stage, study finds.Nature. 2023 Jul;619(7971):682-683. doi: 10.1038/d41586-023-02321-1. Nature. 2023. PMID: 37460689 No abstract available.
-
Advances on biological markers in early diagnosis of Alzheimer disease.Adv Clin Chem. 2005;39:107-29. doi: 10.1016/s0065-2423(04)39004-9. Adv Clin Chem. 2005. PMID: 16013669 Review. No abstract available.
Cited by
-
Translational Medicine in Alzheimer's Disease: The Journey of Donanemab From Discovery to Clinical Application.Chronic Dis Transl Med. 2024 Dec 16;11(2):105-116. doi: 10.1002/cdt3.155. eCollection 2025 Jun. Chronic Dis Transl Med. 2024. PMID: 40486952 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
